6 years of historical data (2019–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Onconetix, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $2M | $3M | $13M | — | — | — |
| Enterprise Value | $17M | $11M | $9M | $-12254999 | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — |
| P/S Ratio | 3.12 | 0.69 | 57.94 | — | — | — | — |
| P/B Ratio | 0.00 | 0.18 | 2.41 | 0.60 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.17 | 149.13 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Onconetix, Inc. earns an operating margin of -2238.0%. Operating margins have expanded from -61634.5% to -2238.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -1065.7% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 41.8% | 41.8% | -1927.9% | — | — | — | — |
| Operating Margin | -2238.0% | -2238.0% | -61634.5% | — | — | — | — |
| Net Profit Margin | -2325.2% | -2325.2% | -63986.5% | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -1065.7% | -1065.7% | -314.5% | -112.6% | -110.6% | -29.8% | -13.7% |
| ROA | -101.5% | -101.5% | -65.7% | -91.3% | -86.6% | -29.4% | -13.5% |
| ROIC | -336.9% | -336.9% | -1603.3% | — | — | -653.0% | — |
| ROCE | -140.8% | -140.8% | -77.7% | -113.1% | -110.4% | -30.2% | -14.7% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $9M ($9M total debt minus $646500 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.98 | 0.98 | 7.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.92 | 3.80 | -1.15 | -1.33 | -0.91 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -40.13 | -40.13 | -53.65 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.05x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 6.69x to 0.05x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | 0.05 | 0.34 | 6.69 | 1.88 | 66.94 | 79.98 |
| Quick Ratio | 0.05 | 0.05 | 0.32 | 6.69 | 1.88 | 66.94 | 79.98 |
| Cash Ratio | 0.04 | 0.04 | 0.26 | 6.57 | 1.18 | 62.75 | 79.87 |
| Asset Turnover | — | 0.09 | 0.00 | — | — | — | — |
| Inventory Turnover | 22.93 | 22.93 | 3.26 | — | — | — | — |
| Days Sales Outstanding | — | 13.93 | 934.78 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Onconetix, Inc. returns 100.0% to shareholders annually — split between a 100.0% dividend yield and 0.0% buyback yield.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 11.9% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.7% | 4.2% | — | — | — |
| Total Shareholder Yield | 100.0% | 12.0% | 1.7% | 4.2% | — | — | — |
| Shares Outstanding | — | $32300 | $5032 | $3609 | $3249 | $3249 | $3249 |
Compare ONCO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ONCOYou | $8M | -0.0 | — | — | 41.8% | -2238.0% | -1065.7% | -336.9% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 6 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ONCO stacks up against sector leader BioNTech SE.
Start ComparisonOnconetix, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Onconetix, Inc.'s return on equity (ROE) is -1065.7%. The historical average is -116.2%.
Based on historical data, Onconetix, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Onconetix, Inc.'s current dividend yield is 100.00%.
Onconetix, Inc. has 41.8% gross margin and -2238.0% operating margin.